Research Analysts Issue Forecasts for NeuroBo Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:NRBO)

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) – Equities researchers at Zacks Small Cap issued their Q1 2024 earnings estimates for NeuroBo Pharmaceuticals in a report issued on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.95) per share for the quarter. The consensus estimate for NeuroBo Pharmaceuticals’ current full-year earnings is ($3.00) per share. Zacks Small Cap also issued estimates for NeuroBo Pharmaceuticals’ Q2 2024 earnings at ($0.95) EPS, Q3 2024 earnings at ($0.97) EPS, Q4 2024 earnings at ($0.97) EPS and FY2026 earnings at ($2.56) EPS.

NeuroBo Pharmaceuticals Stock Performance

NASDAQ NRBO opened at $3.10 on Thursday. NeuroBo Pharmaceuticals has a twelve month low of $2.89 and a twelve month high of $6.75. The stock has a fifty day simple moving average of $4.51 and a 200 day simple moving average of $3.97.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.